miR-24 may be a negative regulator of menin in lung cancer

YUNHU PAN1*, HONGMEI WANG2*, DEBIN MA3*, ZHIYU JI1, LIMIN LUO1, FANGYU CAO1, FANGFANG HUANG1, YANGYANG LIU4, YUSHU DONG4 and YITAN CHEN1

1Department of Respiratory Medicine, No. 92 Hospital of PLA, Nanping, Fujian 341000; 2Department of Hematology, No. 463 Hospital of PLA, Shenyang, Liaoning 110840; 3Department of Respiratory Medicine; 4Institute of Neuroscience, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning 110840, P.R. China

Received June 29, 2017; Accepted March 7, 2018

DOI: 10.3892/or.2018.6327

Abstract. The incidence of lung cancer in China increases annually, and effective targets for the diagnosis and treatment of lung cancer are urgently needed. miRNAs are currently considered to be involved in the regulation of tumor development and growth. miR-24 has been found to contribute to the development of several tumors. Menin is a key tumor suppressor gene, and its expression is generally low in lung cancer. The effects of miR-24 on the biological behavior of lung cancer cells were detected by MTT and Transwell assays. In the present study, miR-24 was found to be associated with menin, affecting the activity of the SMAD3 pathway in lung cancer by inhibiting menin expression. miR-24 may promote the growth and metastasis and inhibit the apoptosis of lung cancer cells by targeting menin. Therefore, the aim of the present study was to provide a new theoretical basis for the targeted therapy of lung cancer.

Introduction

According to WHO statistics, the incidence of lung cancer in China increases annually by ~25% (1,2). Mutations of key proto-oncogenes, such as K-ras, ALK and EGFR, and tumor-suppressor genes, such as p53, are important molecular mechanisms underlying the occurrence of lung cancer (3-7).

In recent years, miRNAs have been attracting increasing attention in the research of tumor pathogenesis, (8-10) and their sensitivity and specificity for the diagnosis of lung cancer have been found to be relatively high (11,12).

Men1, a critical tumor suppressor gene in multiple endocrine neoplasia type 1, encodes a recently identified protein, menin, of which the emerging roles in cancer development have been attracting increasing attention (13). It has also been reported that menin plays a role in suppressing hyperplasia or tumor development in several other organs, such as the lung, prostate and breast, and it exacerbates diabetes in mouse models (14). However, the molecular mechanisms underlying the role of menin in lung cancer remain unclear.

miR-24 is reportedly able to promote the development of several types of tumors. For example, miR-24 promoted the proliferation and inhibited the apoptosis of HeLa cells (15,16), and has also been found to be highly expressed in Hodgkin's lymphoma (17-21). However, the association between miR-24 and menin has not yet been fully elucidated.

In the present study, the RNA expression of miR-24 and menin in lung cancer and adjacent tissues were observed, and it was demonstrated that miR-24 also promotes cell growth and metastasis by targeting menin.

Materials and methods

Tissue samples and cell lines. A total of 70 samples of tumor tissues and adjacent tissues (≥2 cm from the tumor) from patients with lung cancer who were diagnosed and treated at the General Hospital of Shenyang Military Command were obtained between May 2013 and June 2015. The study protocols were approved by the Ethics Committee of the General Hospital of Shenyang Military Command. Patient consent was obtained in writing according to institutional regulations.

A549 and NCI-H446 cells (obtained from the Wuhan Cell Bank) were maintained in Dulbecco’s modified Eagle’s medium (Gibco; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Chicago, IL, USA), 1% penicillin/streptomycin, 1% L-glutamine, under 5% CO2 at 37°C.

Key words: miR-24, menin, lung cancer, SMAD3
**Transfections.** A549 and NCI-H 446 cells (1x10^5) were plated in 6-well plates and transfected with 100 nM of miR-24 mimic (UUGCUGAGUCAGGAGGCAAG) or miR-24 inhibitor (UGAUCCUUGACUCUGGG) according to the manufacturer’s protocol. Transfections were performed 24 h after Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific) according to the manufacturer’s protocol. Menin, menin-del, and menin-wt were transfected into cells with Lipofectamine 2000, and the experiments were conducted after 24 h.

**MTT assays.** Cells were seeded at a density of 1x10^3 cells/well in 96-well plates, and transfected with different miRNAs. The MTT assay was performed 24 h later, using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) to evaluate cell proliferation. The optical densities of the samples were measured at 490 nm.

**Hoechst 33258 assay.** After transfection for 24 h, washing with PBS, and addition of 1 µl (1 mg/ml) Hoechst 33258 for 10 min, the samples were examined using fluorescence microscopy.

**Transwell assay.** Modified Boyden chambers with polycarbonate Nuclepore™ membranes (Corning Inc., Corning, NY, USA) were used to perform metastaesis assays according to the manufacturer’s protocol. After 24 h, the transfected cells were seeded in Transwell chambers in serum-free media with or without Matrigel coating, while medium containing 30% fetal bovine serum was placed in the lower well. After 24 h, the cells were washed with PBS, fixed with methanol for 20 min, stained with crystal violet dye for 10 min and then counted under a light microscope.

**Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).** RNA was extracted from tissue samples or cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol. cDNA synthesis was performed with the High-Capacity cDNA synthesis kit (Takara Bio, Inc., Otsu, Japan). RT-qPCR analysis was performed on an Applied Biosystems 7500 Real-Time PCR System according to the manufacturer’s instructions (33). Primer sequences are shown in Table I. All the reactions were performed as previously described (34).

**Western blot analysis.** Tissues and cells were scraped and lysed in RIPA buffer (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). To determine the levels of different proteins, 30 µg of protein from each sample was subjected to 10% SDS-PAGE and transferred onto a nitrocellulose membrane (Corning Inc.). Target proteins were probed with specific antibodies against menin (1:1,000; cat. no. sc-374371), SMAD3 (1:1,000; cat. no. sc-4709), Bcl-2 (1:1,000; cat. no. sc-22657), Bax (1:1,000; cat. no. sc-22657), MMP2 (1:1,000; cat. no. sc-3594), and GAPDH (1:5,000; cat. no. sc-365062) (all from Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

**Dual-luciferase reporter assay.** Dual-luciferase activity assays were performed as previously described (35). The menin 3′-untranslated region (UTR) was PCR-amplified and cloned into the pMIR-REPORT™ vector (Ambion; Thermo Fisher Scientific). The sequences were as follows: Menin-wt forward, 5′-TCGACAGCAACCTGATCT-3′ and reverse, 5′-ACACCGGAGCTGTATTTCAATTT-3′; and menin-del forward, 5′-CTGACAGCAACCTGATCT-3′ and reverse, 5′-GCCATGGGTACCTTCAG-3′. A549 cells were co-transfected with menin-wt or -del reporter vector and control plasmid in miR-24 mimic and miR-24 AS (antisense). Luciferase activity was determined with the Dual-Luciferase Reporter Assay System (Promega Corp., Madison, WI, USA) after 36 h of transfection.

**Statistical analysis.** All experiments were repeated at least three times. A correlation analysis with the log-rank test was used to evaluate the differences in the levels of possible prognostic factors. Statistical significance was evaluated with the two-tailed Student’s t-test comparing two groups of data. Asterisks indicate significant differences of experimental groups compared with the corresponding control condition. Statistical analysis was performed using GraphPad Prism software (GraphPad, Inc., La Jolla, CA, USA) and statistical significance was defined as P<0.05.

**Results**

**Association of miR-24 and menin in lung cancer.** The results revealed that the expression of miR-24 in the tumor tissues was found to be higher compared with that in the adjacent tissues of 70 lung cancer patients as determined by qPCR (Fig. 1A). The results of the Kaplan-Meier analysis demonstrated that patients with high miR-24 expression had a significantly decreased overall survival (Fig. 1B). Next, we observed that miR-24 was closely associated with the development of lung cancer. There was a correlation between miR-24 and the size of the tumor (Table II). Biological software (miRDB) predicted that miR-24 may target menin. Based on that finding, we analyzed the expression of menin in cancer tissues and adjacent tissues in the patients by qPCR (Fig. 1C). The results revealed that the expression level of menin was lower in tumor tissues than in adjacent normal tissues. In the Kaplan-Meier analysis, we observed that patients with a high expression of menin survived longer (Fig. 1D). It was also observed that miR-24 and menin were negatively correlated in these patients (Fig. 1E). Using the miRDB software, we identified a binding site in the 3′-UTR region of menin for miR-24 (Fig. 1F). The luciferase reporter assay demonstrated that the activity of menin was significantly inhibited following co-transfection with miR-24. This inhibitory effect was eliminated when the 3′-UTR region of menin was mutated. Furthermore, transfection with the miR-24 antisense strand did not inhibit the activity of menin (Fig. 1G).

**miR-24 promotes the proliferation of lung cancer cells.** The miR-24 mimic/inhibitor was transfected into lung cancer cells, and the effect of miR-24 on proliferation was then evaluated by MTT assay (Fig. 2A and B). It was observed that the proliferation of lung cancer cells was stimulated when miR-24 was overexpressed. Menin, SMAD3 and cyclin D1 were assessed...
when miR-24 was overexpressed in A549 cells (Fig. 2C and D). The results demonstrated that miR-24 inhibited the expression of menin, and it also upregulated SMAD3 and cyclin D1 expression. In turn, when miR-24 was inhibited in A549 cells, menin expression was increased (Fig. 2E and F), whereas SMAD3 and cyclin D1 expression levels in A549 cells were decreased.

**miR-24 inhibits the apoptosis of lung cancer cells.** Since miR-24 affects menin to regulate the proliferation of lung cancer cells, it was hypothesized that the apoptosis of lung cancer cells may also be affected by targeting menin. When miR-24 was overexpressed in A549 cells (Fig. 2C and D), Hoechst 33258 staining revealed that miR-24 significantly inhibited the apoptosis of A549 cells. Next, we examined the protein and mRNA levels of menin, SMAD3, Bcl-2 and Bax in A549 cells overexpressing miR-24 (Fig. 3C and D). The results demonstrated that Bcl-2 expression was increased, whereas Bax expression was inhibited at both the protein and mRNA levels after miR-24 inhibitor was transfected into A549 cells (Fig. 3E and F).

**miR-24 promotes the metastasis of lung cancer cells.** Transwell assays (with or without Matrigel) were used to investigate the metastasis of lung cancer cells. Transwell assays (with or without Matrigel) were used to investigate
whether miR-24 is involved in the metastasis of lung cancer cells (Fig. 4A-D). A miR-24 mimic or miR-24 inhibitor was transfected into A549 and NCI-H446 cells. Subsequently, the Transwell results demonstrated that the migration and invasion of A549 and NCI-H446 cells were significantly enhanced when miR-24 was overexpressed; however, the migration and invasion of A549 and NCI-H446 cells were inhibited when miR-24 expression was decreased. Furthermore, the protein
and mRNA levels of menin, SMAD3 and MMP2 were assessed by western blotting and qPCR when the expression of miR-24 was up- or downregulated in A549 cells (Fig. 4E-H). The results indicated that menin was significantly downregulated, whereas SMAD3 and MMP2 were significantly upregulated by miR-24.
Discussion

Despite the continuous development of early diagnostic and treatment methods for lung cancer, the 5-year survival rate of lung cancer remains <50% according to the WHO (22,23). Thus, early detection and timely treatment are crucial for lung cancer patients.

miRNAs are endogenous, small, non-coding, regulatory RNAs that have attracted attention in recent years. A number of reports have indicated that the expression of miRNAs is closely associated with cancer development.

miR-24 has been demonstrated to promote the development of several tumors. In hepatocellular carcinoma (HCC), miR-24 functions as an oncogene, at least in part by promoting cell invasion through downregulation of p53 (24), and miR-24-3p plays an important role in the initiation and progression of HCC by targeting metallothionein 1M (25). It has also been demonstrated that exosomal miR-24-3p is involved in tumor pathogenesis by mediating T-cell suppression via repression of FGF11, and may serve as a potential prognostic biomarker in nasopharyngeal cancer (NPC) (26). Additionally, it was reported that miR-24-3p significantly inhibited N87 cell growth, migration and invasion, and promoted apoptosis (27).

Zhao et al reported that miR-24 may serve as a novel potential biomarker for the prognosis of TSCC patients through targeting FBXW7 (28). It was also demonstrated that miR-24 acts as a tumor suppressor in NPC through targeting FSCN1 (29). In lung cancer, miR-24 may promote cell proliferation by targeting NAIF1 (19). Downregulation contributes to vP16-DDP resistance by targeting ATG4A (21) and enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling (30). All these findings indicate that miR-24 may play an important role in the regulation of lung cancer.

Menin regulates cell proliferation, apoptosis, metastasis and gene transcription. Menin mutations have been detected in 35% of tumors. One of the proteins interacting with menin is β-catenin, which acts as a transcription factor, and its dysregulation may be associated with the development and progression of several tumors (31). It has also been reported that menin can interact with K-Ras, SMAD3 and TGF-β to exert a biological effect. In human studies, menin expression was found to be lower in lung adenocarcinoma samples, and
it may mediate repression of lung cancer and provide a novel potential target for treating menin-negative and Ras-active lung adenocarcinoma (32).

In our experiments, tumor tissues and adjacent tissues from 70 patients with lung cancer were analyzed. The analysis results revealed that miR-24 expression in the
tumor tissues was significantly higher compared with that in adjacent tissues, whereas menin expression in the tumor tissues was lower compared with that in the adjacent tissues. In addition, we observed that patients with higher expression of miR-24 had a shorter 5-year survival. By comparison, patients with a higher content of menin survived longer. Thus, it was inferred that miR-24 may be associated with the expression of menin. miR-24 and menin were found to indirectly interact with each other, thereby promoting the growth and metastasis of lung cancer cells. The regulatory effect of miR-24 on the growth of lung cancer cells was at least partially realized by targeting menin. The regulatory role of miR-24 in lung cancer was demonstrated through experiments in vitro, and in future experiments our results may be further confirmed in vivo. For the in vivo experiments, a nude mice tumor-bearing model may be constructed, followed by expressing miR-24 in nude mice to detect the proliferation of tumor cells. A mouse lung cancer model may also be constructed to detect the invasion of lung cancer cells overexpressing miR-24.

In summary, we demonstrated that the promotion of the growth and metastasis of lung cancer cells by miR-24 is at least partly mediated by the regulation of menin. Our findings provide a new theoretical basis for the diagnosis and treatment of lung cancer.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Key Research Project of Nanjing Military Area Command (grant no. 14ZD32) and the Liaoning Provincial Natural Science Foundation of China (grant no. 201601217).

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

YP and HW conceived and designed the study. ZJ, YD, YC and DM performed the experiments. LSH and JHW wrote the paper. LL, FC, FH and YL reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The study protocols were approved by the Ethics Committee of the General Hospital of Shenyang Military Command. Patient consent was obtained in writing according to institutional regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


